# Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma

> **NCT00698243** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 128 (actual)

## Conditions studied

- Any Solid Tumor or Lymphoma

## Interventions

- **DRUG:** OSI-027

## Key facts

- **NCT ID:** NCT00698243
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2013-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00698243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00698243, "Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00698243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*